Search Results - "Vadlamudi, RK"

Novel KDM1A inhibitors induce differentiation and apoptosis of glioma stem cells via unfolded protein response pathway by Sareddy, G R, Viswanadhapalli, S, Surapaneni, P, Suzuki, T, Brenner, A, Vadlamudi, R K

“…Glioma stem cells (GSCs) have a central role in glioblastoma (GBM) development and chemo/radiation resistance, and their elimination is critical for the…”
Get full text

Abstract P2-02-03: FASN inhibition as a potential treatment for therapy of endocrine resistant breast cancer by Gruslova, A, Sareddy, GR, Vadlamudi, RK, Viswanadhapalli, S, Brenner, A

“…Abstract INTRODUCTION: Fatty acid synthase (FASN) is a key enzyme in tumor cell biology controlling endogenous lipid biosynthesis. It is overexpressed in a…”
Get full text

Abstract P1-09-09: Efficacy of estrogen receptor β agonists in the prevention of breast cancer progression to therapy resistance by Ramasamy, K, Samayoa, C, Krishnegowda, NK, Vadlamudi, RK, Tekmal, RR

“…Abstract Estrogen plays an important role in the initiation and progression of breast cancer (BCa). Approximately, 70% of breast tumors are estrogen receptor…”
Get full text

Abstract P5-07-05: Oncogene PELP1 regulates alternative splicing in breast cancer through PRMT6 by Mann, M, Vadlamudi, RK

“…Abstract Background: Alternative splicing (AS) is essential in regulating gene expression and protein diversity; however, dysregulation leads to cancer…”
Get full text

Abstract P1-04-01: Estrogen receptor β agonists inhibits syngeneic mammary tumor growth through cell-cycle arrest by modulating cell-cycle regulators by Ramasamy, K, Samayoa, C, Krishnegowda, NK, Thurlapati, A, Vadlamudi, RK, Tekmal, RR

“…Abstract Breast Cancer is the main cause of cancer-associated mortality in women worldwide. The estrogen receptors (ER's) play an important role in normal…”
Get full text

Abstract P6-11-15: Pre-clinical investigation of estrogen receptor β agonists for the treatment of breast cancer by Samayoa, C, Krishnegowda, NK, Vadlamudi, RK, Tekmal, RR

“…Abstract Breast Cancer is the primary cause of cancer-associated mortality worldwide, and in United States alone, more than 250,000 women are diagnosed every…”
Get full text

Abstract P4-15-02: Investigating the use estrogen receptor β agonists in the prevention of breast cancer using a transgenic mouse model by Samayoa, C, Krishnegowda, NK, Vadlamudi, RK, Tekmal, RR

“…Abstract Breast cancer is the most common cancer among women worldwide. In the United States, 1 in 8 women will develop breast cancer during her lifetime, and…”
Get full text

Abstract P4-07-01: A small molecule inhibitor (ERX-41) induces endoplasmic reticulum stress in triple negative breast cancer by Liu, X, Viswanadhapalli, S, Ma, S, Lee, T-K, Sareddy, GR, Ekoue, DN, Blatt, EM, Zhou, M, Li, M, Tekmal, RR, Ahn, J-m, Vadlamudi, RK, Raj, GV

“…Abstract Background: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer and represents a disproportional share of the breast cancer…”
Get full text

Abstract P1-06-09: Proto-oncogene PELP1 signaling regulates breast cancer stem cells via G9a/EHMT2 by Viswanadhapalli, S, Mann, M, Sareddy, GR, Xaionan, L, Vankayalapati, H, Brann, D, Vadlamudi, RK

“…Abstract BACKGROUND: Evolving evidence suggests that cancer stem cells (CSCs) evade hormonal therapy and therapy resistance occurs due to regrowth of tumor…”
Get full text

Pak1 phosphorylation of snail, a master regulator of epithelial-to-mesenchyme transition, modulates snail's subcellular localization and functions by ZHIBO YANG, RAYALA, Suresh, NGUYEN, Diep, VADLAMUDI, Ratna K, SHIUAN CHEN, KUMAR, Rakesh

“…The process of epithelial-mesenchymal transition plays a pivotal role in the conversion of early stage tumors into invasive malignancies, and has been shown to…”
Get full text

Abstract P1-09-06: Blocking ER coregulator signaling enhances CDK4/6 inhibitor palbociclib therapy in ER-positive advanced breast cancer by Viswanadhapalli, S, Sareddy, GR, Zhou, M, Ali, E, Li, X, Ma, S-H, Lee, T-K, Tekmal, RR, Ahn, J-M, Raj, GV, Vadlamudi, RK

“…Abstract BACKGROUND: Recently,CDK4/6 inhibitors in combination with endocrine therapy (AE/AI/SERDs) is approved for the treatment of ER+ advanced breastcancer…”
Get full text

Abstract P5-04-23: Enhancing the activity of a novel estrogen receptor coregulator binding modulator (ERX-11) against ER-positive therapy resistant breast cancer by Viswanadhapalli, S, Ma, S, Lee, T-K, Sareddy, GR, Liu, X, Ekoue, D, Alluri, A, Luo, Y, Kassees, K, Arteaga, C, Alluri, P, Weintraub, SE, Tekmal, RR, Ahn, J-M, Raj, GV, Vadlamudi, RK

“…Abstract Background:We had previously reported a novel small molecule, ERX-11, that directly interacts with ER and blocks the interaction between a subset of…”
Get full text

Abstract P2-06-02: Development of a first-in-class small molecule inhibitor (EC359) targeting oncogenic LIF/LIFR signaling for the treatment of triple negative breast cancer by Viswanadhapalli, S, Luo, Y, Sareddy, GR, Santhamma, B, Zhou, M, Li, M, Pratap, UP, Altwegg, KA, Li, X, Srinivasan, U, Ma, S, Chang, A, Riveros, AC, Zhang, KY, Dileep, KV, Pan, X, Murali, R, Bajda, M, Raj, G, Brenner, A, Manthati, V, Rao, M, Tekmal, RR, Nair, HB, Nickisch, KJ, Vadlamudi, RK

“…Abstract Background: Leukemia inhibitory factor (LIF) and its receptor LIFR are over-expressed in multiple solid tumors and play a key role in tumor growth,…”
Get full text

Abstract P2-05-01: Induction of PELP1 expression in mammary gland promotes tumorigenesis by enhancing CDK-CyclinD1 signaling by Vadlamudi, RK, Cortez, VA, Zamora, A, Martinez, L, Tekmal, RR

“…Abstract Introduction: Estrogen receptor coregulator over-expression promotes carcinogenesis and/or progression of endocrine related-cancers where steroid…”
Get full text

Abstract P5-09-14: Plant-derived estrogen receptorb agonists alone or in combination with aromatase inhibitors restore sensitivity in endocrine therapy resistant breast tumors by Samayoa, C, Krishnegowda, NK, Vadlamudi, RK, Tekmal, RR

“…Abstract Estrogen receptors (ER) play an important role in breast cancer. Over two-thirds of all breast cancers express ERa, and current endocrine therapies…”
Get full text

Abstract P6-06-04: Targeting replication stress in triple negative breast cancer treatment regimen: An emerging approach by Rajamanickam, S, Park, JH, Bates, K, Timilsina, S, Eedunuri, VK, Onyeagucha, B, Subbarayalu, P, Abdelfattah, N, Jung, KH, Favours, E, Mohammad, TA, Chen, H-IH, Vadlamudi, RK, Chen, Y, Kaipparettu, BA, Arbiser, JL, Rao, MK

“…Abstract Triple-negative breast cancers (TNBCs) represent aggressive heterogeneous subtype of breast cancer with poor clinical outcome. TNBCs have been…”
Get full text

Filamin is essential in actin cytoskeletal assembly mediated by p21-activated kinase 1 by Kumar, Rakesh, Vadlamudi, Ratna K, Li, Feng, Adam, Liana, Nguyen, Diep, Ohta, Yasutaka, Stossel, Thomas P

“…The serine/threonine kinase p21-activated kinase 1 (Pak1) controls the actin cytoskeletal and ruffle formation through mechanisms that are independent of…”
Get full text

Abstract P4-16-10: A novel paclitaxel-dendrimer conjugate demonstrates better efficacy in breast cancer models by Satsangi, A, Roy, SS, Satsangi, RK, Vadlamudi, RK, Ong, JL

“…Abstract BACKGROUND: Breast cancer is the 2nd most common cause of cancer deaths in women. Chemotherapy is an important treatment modality. Yet, delivery of…”
Get full text

Abstract P1-05-10: Targeting breast cancer metastasis through disruption of novel PELP1-G9a complex by Mann, M, Chakravarty, D, Kim, CA, Vadlamudi, RK

“…Abstract Although there are several therapies available for the treatment of breast cancer, many patients have tumor recurrences that ultimately metastasize…”
Get full text

Emerging functions of p21-activated kinases in human cancer cells by Kumar, Rakesh, Vadlamudi, Ratna K.

“…The p21 activated kinases (Paks), an evolutionarily conserved family of serine/threonine kinases, are important for a variety of cellular functions including…”
Get full text